<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6601">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01979003</url>
  </required_header>
  <id_info>
    <org_study_id>202459</org_study_id>
    <nct_id>NCT01979003</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Determine the Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion</brief_title>
  <official_title>A Pilot Study to Determine the Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if Fluorescein systemic injection during hysterectomy procedure can be useful
      in revealing the depth of endometrial cancer invasion.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Efficacy of using fluorescein dye to determine depth of invasion compared to using frozen section and final pathology.</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>For each study subject the paired difference in invasion depths determined using the Systemic Fluorescein Injection (SFI) versus Frozen Section (FS) methods will calculated and expressed as a percentage of the FS-based invasion depth.</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Endometrial Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorescein</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented endometrial cancer and scheduled for hysterectomy as part of their
             treatment.

          -  No known allergy to fluorescein dye

          -  Ability to understand and sign informed consent

          -  18 years of age or older

        Exclusion Criteria:

          -  Prior hysterectomy

          -  Known sensitivity to fluorescein dye
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Burnett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Burnett, MD</last_name>
    <phone>501-296-1099</phone>
    <email>ABurnett@uams.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cynthia Walton</last_name>
    <phone>501-686-8274</phone>
    <email>waltoncynthial@uams.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Burnett, MD</last_name>
      <phone>501-296-1099</phone>
      <email>ABurnett@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Walton</last_name>
      <phone>501-686-8274</phone>
      <email>waltoncynthial@uams.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>October 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Sarcoma, Endometrial Stromal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
